POP-D75 mcg

POP-D is a progestin-only oral contraceptive (commonly called a "mini-pill") used for:

• Prevention of pregnancy (established/approved use): POP-D 75 microgram tablets are indicated for women of reproductive age who choose a progestin-only method of contraception, including those who cannot or prefer not to take estrogen-containing combined oral contraceptives (e.g., breastfeeding women, smokers over 35 years of age, or women with certain cardiovascular risk factors).
• Contraception during breastfeeding (guideline-supported use): Progestin-only pills such as POP-D are preferred over combined hormonal contraceptives in breastfeeding women because they do not significantly affect milk production.

POP-D does not protect against sexually transmitted infections (STIs), including HIV.

Each film-coated tablet contains Desogestrel 75 micrograms (0.075 mg) as the active ingredient, along with pharmaceutically inert excipients such as lactose, potato starch, povidone, colloidal silicon dioxide, stearic acid, and a film-coating system.

POP-D is a synthetic progestin (a third-generation 19-nortestosterone derivative) used alone as a progestin-only oral contraceptive. Unlike combined oral contraceptives, POP-D-only tablets contain no estrogen and are taken continuously, with no hormone-free interval, allowing use in women for whom estrogen is undesirable or contraindicated.

POP-D belongs to the therapeutic class of hormonal contraceptives – progestin-only oral contraceptives ("mini-pills").

Desogestrel is a potent, selective progestin. After absorption, it is rapidly converted to its active metabolite, etonogestrel, which binds with high affinity to progesterone receptors.

Unlike older progestin-only pills, Desogestrel-only tablets (75 mcg) reliably inhibit ovulation in most cycles, which is the primary contraceptive mechanism. Additional effects contributing to efficacy include:

• Thickening of cervical mucus, impairing sperm penetration.
• Alteration of the endometrium, making implantation less likely.

Pharmacokinetics: Desogestrel is well absorbed orally and undergoes extensive first-pass metabolism to etonogestrel, the biologically active moiety. Etonogestrel is highly protein-bound (mainly to sex hormone-binding globulin) and is eliminated with a half-life of approximately 30 hours, mainly via metabolism and excretion in urine and feces.

POP-D tablets should be swallowed whole with water, at approximately the same time every day, with or without food. Taking the tablet more than 12 hours late reduces contraceptive protection — see Dosage and Administration for the recommended action.

The contraceptive effectiveness of POP-D may be reduced by drugs that induce hepatic (liver) enzymes (particularly CYP3A4), which increase the metabolism of POP-D. These include:

• Rifampicin/rifabutin (used for tuberculosis) — significant reduction in efficacy.
• Certain anticonvulsants — phenytoin, carbamazepine, barbiturates, primidone, oxcarbazepine, topiramate.
• Some antiretroviral/antiviral medicines used for HIV or hepatitis C.
• St. John's Wort (herbal supplement).

Women taking these medicines long-term should use an additional or alternative non-hormonal method of contraception during treatment and for 28 days after stopping the interacting medicine.

Conversely, POP-D may lower blood levels of lamotrigine, potentially reducing seizure control in women with epilepsy; a dose adjustment of lamotrigine may be needed under medical supervision.

The most common side effect of POP-D is a change in the pattern of menstrual bleeding (irregular bleeding/spotting, or absence of periods), which is the most frequent reason for discontinuation. Other reported side effects include:

• Headache
• Nausea
• Breast tenderness or pain
• Mood changes, including low mood or decreased libido
• Acne
• Weight change
• Functional ovarian cysts (usually asymptomatic and resolve without treatment)

Seek prompt medical attention for severe abdominal pain, signs of blood clots (leg swelling/pain, chest pain, sudden breathlessness), or jaundice.

Pregnancy: POP-D is not indicated for use during pregnancy and should be discontinued if pregnancy is confirmed or suspected. There is no proven need for specific action if POP-D is inadvertently taken in early pregnancy, but a physician should be consulted; use only if clearly needed and after discussing risks and benefits with a doctor.

Lactation: POP-D is generally considered a preferred contraceptive choice during breastfeeding, as progestin-only methods have minimal effect on milk volume or composition, unlike estrogen-containing contraceptives. Small amounts of the active metabolite pass into breast milk; no adverse effects on infant growth or development have been established, but use should be guided by a physician, especially in the early postpartum period.

Use POP-D with caution in the following situations, and consult a physician:

• History of ectopic pregnancy: if pregnancy occurs during use, the relative likelihood of ectopic pregnancy is increased; seek prompt evaluation for lower abdominal pain.
• Timing of doses: contraceptive efficacy depends on strict adherence to the daily schedule; see Dosage and Administration for missed-dose guidance.
• Ovarian cysts: functional cysts may occur and usually resolve spontaneously; surgery is rarely required.
• Irregular bleeding: common, especially in the first months of use; persistent or heavy bleeding should be evaluated to exclude other causes.
• Reduced efficacy with enzyme-inducing drugs: see Interaction.

POP-D does not protect against sexually transmitted infections; barrier methods should be used for STI prevention.

No serious harmful effects have been reported from taking an excess dose of POP-D. Possible symptoms of overdose may include nausea, vomiting, or, in females, withdrawal-type vaginal bleeding. There is no specific antidote. If overdose is suspected, seek immediate medical attention or contact a poison control center; treatment is supportive and symptomatic.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Hepatic impairment: Contraindicated in women with active severe liver disease or liver tumors (see Contraindications); use with caution in women with a history of liver disease and monitor liver function.

Renal impairment: No dose adjustment is generally required, though data are limited; use with caution.

Elderly: Not applicable — POP-D is intended for contraception in women of reproductive age and is not used in postmenopausal women.

Pediatric use: See Pediatric Uses.

Obesity: Contraceptive efficacy may be somewhat reduced in women with a high body mass index; alternative or additional contraceptive measures may be discussed with a physician.

POP-D may be used continuously for as long as contraception is desired, taken without interruption between packs. Use should be reviewed periodically (e.g., at least annually) with a physician to reassess suitability, tolerability, and any new risk factors.

Progestin (progestogen); progestin-only oral contraceptive; synthetic 19-nortestosterone derivative.

Desogestrel acts mainly by inhibiting ovulation, and additionally thickens cervical mucus and alters the endometrium; see Pharmacology for full mechanistic detail.

X

POP-D is indicated only in females who have started menstruating (post-menarche) and require contraception. Safety and efficacy have not been established in pre-menarchal children, for whom there is no indication for use. Use in adolescents of reproductive age follows the same dosing as adults, with attention to counseling on correct, consistent use.